BRAF and melanoma: Additionally, TOO identification can inform potential clinically relevant resistance mechanisms; for example, melanoma patients with a BRAF V600E mutation are known to benefit from combination BRAF and MEK inhibitors, whilst colorectal patients with the same alteration don’t derive similar benefit [43].